Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial

European Urology

Volumn 66, Issue 2, 2014, Pages 243-250

  Wiegel, Thomas ^a   Bartkowiak, Detlef ^a   Bottke, Dirk ^a   Bronner, Claudia ^a   Steiner, Ursula ^b   Siegmann, Alessandra ^b   Golz, Reinhard ^c   Störkel, Stephan ^c   Willich, Normann ^d   Semjonow, Axel ^d   Stöckle, Michael ^e   Rübe, Christian ^e   Rebmann, Udo ^f   Kälble, Tilman ^g   Feldmann, Horst Jürgen ^g   Wirth, Manfred ^h   Hofmann, Rainer ⁱ   Engenhart Cabillic, Rita ⁱ   Hinke, Axel ^j   Hinkelbein, Wolfgang ^b   Miller, Kurt ^b   more..

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c HELIOS KLINIKUM WUPPERTAL   (Germany)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^e SAARLAND UNIVERSITY   (Germany)

^f Diakonissenkrankenhaus Dessau   (Germany)

^g KLINIKUM FULDA   (Germany)

^h UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

ⁱ UNIVERSITY HOSPITAL MARBURG   (Germany)

^j WiSP GmbH   (Germany)

more..

Author keywords

Adjuvant radiotherapy; Prostate cancer; Prostate specific antigen; Radical prostatectomy; Wait and see

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; AGED; ARTICLE; BLADDER DISEASE; BLADDER TOXICITY; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISTANT METASTASIS; FOLLOW UP; GLEASON SCORE; HUMAN; INTENTION TO TREAT ANALYSIS; INTERMETHOD COMPARISON; LIMIT OF DETECTION; LINEAR ACCELERATOR; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; RADIOTHERAPY UNIT; RANDOMIZED CONTROLLED TRIAL (TOPIC); TOXICITY; URETHRA STRICTURE; URINE INCONTINENCE; ADENOCARCINOMA; ADJUVANT THERAPY; ADVERSE EFFECTS; BLOOD; CANCER STAGING; COMPARATIVE STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; PATHOLOGY; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIAL; SALVAGE THERAPY; SURVIVAL RATE; TIME; WATCHFUL WAITING;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASM, RESIDUAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; SALVAGE THERAPY; SURVIVAL RATE; TIME FACTORS; WATCHFUL WAITING;

EID: 84904035686     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2014.03.011     Document Type: Article

References (30)

1. A.S. Kibel, J.P. Ciezki, and E.A. Klein et al. Survival among men with clinically localized prostate cancer treated with radical prostatectomy or radiation therapy in the prostate specific antigen era J Urol 187 2012 1259 1265
2. A.J. Stephenson, M. Bolla, and A. Briganti et al. Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy Eur Urol 61 2012 443 451
3. C.T. Nguyen, A.M. Reuther, A.J. Stephenson, E.A. Klein, and J.S. Jones The specific definition of high risk prostate cancer has minimal impact on biochemical relapse-free survival J Urol 181 2009 75 80
4. S.A. Boorjian, R.H. Thompson, and M.K. Tollefson et al. Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence Eur Urol 59 2011 893 899
5. I.M. Thompson, C.M. Tangen, and J. Paradelo et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial J Urol 181 2009 956 962
6. M. Bolla, H. van Poppel, and B. Tombal et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911) Lancet 380 2012 2018 2027
7. T. Wiegel, D. Bottke, and U. Steiner et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95 J Clin Oncol 27 2009 2924 2930
8. C.R. Pound, A.W. Partin, M.A. Eisenberger, D.W. Chan, J.D. Pearson, and P.C. Walsh Natural history of progression after PSA elevation following radical prostatectomy JAMA 281 1999 1591 1597
9. P. Hermanek, and L.H. Sobin TNM classification of malignant tumours ed. 4. 1992 Springer New York, NY
10. World Health Organization WHO handbook for reporting results of cancer treatment 1979 WHO Geneva, Switzerland
11. D. Bottke, R. Golz, and S. Storkel et al. Phase 3 study of adjuvant radiotherapy versus wait and see in pT3 prostate cancer: impact of pathology review on analysis Eur Urol 64 2013 193 198
12. A. Siegmann, D. Bottke, and J. Faehndrich et al. Salvage radiotherapy after prostatectomy-what is the best time to treat? Radiother Oncol 103 2011 239 243
13. A. Briganti, T. Wiegel, and S. Joniau et al. Early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis Eur Urol 62 2012 472 487
14. C.R. King The timing of salvage radiotherapy after radical prostatectomy: a systematic review Int J Radiat Oncol Biol Phys 84 2012 104 111
15. D. Bottke, D. Bartkowiak, M. Schrader, and T. Wiegel Radiotherapy after radical prostatectomy: immediate or early delayed? Strahlenther Onkol 188 2012 1096 1101
16. Briganti A, Karnes RJ, Joniau S, et al. Prediction of outcome following early salvage radiotherapy among patients with biochemical recurrence after radical prostatectomy. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo. 2013.11.045.
17. P. Ost, N. Lumen, and A.S. Goessaert et al. High-dose salvage intensity-modulated radiotherapy with or without androgen deprivation after radical prostatectomy for rising or persisting prostate-specific antigen: 5-year results Eur Urol 60 2011 842 849
18. C. Parker, N. Clarke, and J. Logue et al. RADICALS (Radiotherapy and Androgen Deprivation in Combination after Local Surgery) Clin Oncol (R Coll Radiol) 19 2007 167 171
19. P. Richaud, P. Sargos, and B. Henriques de Figueiredo et al. Postoperative radiotherapy of prostate cancer [in French] Cancer Radiother 14 2010 500 503
20. Trans-Tasman Radiation Oncology Group (TROG). Radiotherapy - Adjuvant Versus Early Salvage (RAVES). ClinicalTrials.gov Web site. http:// clinicaltrials.gov/ct2/show/NCT00860652.
21. S.M. Chan, F.J. Garcia, J.L. Chin, M. Moussa, and M.Y. Gabril The clinical significance of in-depth pathological assessment of extraprostatic extension and margin status in radical prostatectomies for prostate cancer Prostate Cancer Prostatic Dis 14 2011 307 312
22. P. Swindle, J.A. Eastham, and M. Ohori et al. Do margins matter? the prognostic significance of positive surgical margins in radical prostatectomy specimens J Urol 179 2008 S47 S51
23. J. Mauermann, V. Fradet, and L. Lacombe et al. The impact of solitary and multiple positive surgical margins on hard clinical end points in 1712 adjuvant treatment-naive pT2-4 N0 radical prostatectomy patients Eur Urol 64 2013 19 25
24. S.E. Eggener, P.T. Scardino, and P.C. Walsh et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy J Urol 185 2011 869 875
25. I.M. Thompson Jr., C.M. Tangen, and J. Paradelo et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial JAMA 296 2006 2329 2335
26. C.M. Moinpour, K.A. Hayden, and J.M. Unger et al. Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy J Clin Oncol 26 2008 112 120
27. A. Goenka, J.M. Magsanoc, and X. Pei et al. Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy Eur Urol 60 2011 1142 1148
28. P. Ost, W. De Gersem, B. De Potter, V. Fonteyne, W. De Neve, and G. De Meerleer A comparison of the acute toxicity profile between two-dimensional and three-dimensional image-guided radiotherapy for postoperative prostate cancer Clin Oncol (R Coll Radiol) 23 2011 344 349
29. C.R. King, and D.S. Kapp Radiotherapy after prostatectomy: is the evidence for dose escalation out there? Int J Radiat Oncol Biol Phys 71 2008 346 350
30. N. Ohri, A.P. Dicker, E.J. Trabulsi, and T.N. Showalter Can early implementation of salvage radiotherapy for prostate cancer improve the therapeutic ratio? A systematic review and regression meta-analysis with radiobiological modelling Eur J Cancer 48 2012 837 844